DesignMechanistic biochemical and metabolomics study combining recombinant human CD38 assays, stable-isotope tracing, and an acute 2×2 mouse intervention with a CD38 inhibitor.
PopulationRecombinant-enzyme systems and 9-week-old male C57BL/6J mice; no human participants.
SampleIn-vivo 2×2 experiment used n=5 mice per group; biochemical experiments were repeated across defined reaction conditions.
InterventionIn vitro NMN/nicotinic-acid substrate experiments with recombinant CD38; in vivo single oral NMN 500 mg/kg with or without oral CD38 inhibitor 78c 10 mg/kg, followed by tissue collection 2 hours later.
EndpointsCD38-dependent conversion of NMN plus nicotinic acid to NaMN; Stable-isotope confirmation of base exchange; Selectivity versus NR/NaR and reverse exchange; Liver, muscle, and kidney NaMN and NaAD after NMN; Effect of CD38 inhibition on NMN-induced deamidated metabolites
What the publication reported
This mechanistic study investigated why administering NMN can raise metabolites from the deamidated Preiss-Handler pathway even though NMN belongs to the amidated salvage pathway.
The authors showed that CD38 can exchange NMN's nicotinamide group for free nicotinic acid, generating nicotinic acid mononucleotide (NaMN). Stable-isotope experiments supported the chemical identity of the reaction, and the reaction was not reproduced with NR or NaR in the same way.
In mice, oral NMN increased NaMN and NaAD in liver and muscle, while coadministration of a CD38 inhibitor abolished those increases. The work identifies a metabolic route but does not quantify how important it is after oral NMN in humans.
Key findings
Recombinant CD38 converted NMN plus nicotinic acid into NaMN through a base-exchange reaction.
Stable-isotope labeling confirmed that the nicotinic-acid ring was incorporated into newly formed NaMN.
The base-exchange reaction was selective for NMN in the tested comparisons and was not detected for NR/NaR under the same experimental framework.
A single oral NMN dose increased NaMN and NaAD in mouse liver and muscle.
The CD38 inhibitor 78c abolished the NMN-induced rise in NaMN and NaAD in liver and muscle, supporting in-vivo relevance of the mechanism.
What it cannot establish
The in-vivo evidence was an acute high-dose mouse experiment, not chronic human oral supplementation.
The study identifies a pathway but does not establish what fraction of orally administered NMN follows this route in people.
Tissue effects differed, including lack of the same NMN-induced deamidated-metabolite spike in kidney.
Biochemical enzyme systems simplify the cellular environment and do not alone define whole-body precursor handling.
One author disclosed advisory and equity interests in companies developing NAD+-related products or technologies.
HealthspanX claim boundary: This study does not establish the dominant route of oral NMN metabolism in humans, human tissue bioavailability, clinical benefit, or equivalence among commercial NMN formulations.
